ReviewCurrent microbiology2026
A Comprehensive Review on Various Mechanisms of Quorum Sensing Inhibition by Gold Nanoparticles.
Review in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to multiple drugs and biofilm-associated infections are major challenges to global health. The ability of gold nanoparticles (AuNPs) to disrupt bacterial quorum sensing (QS) mechanisms, reduce virulence, and inhibit biofilm formation without inducing resistance makes them a promising alternative for treating these infections. The potential of AuNPs as quorum-sensing inhibitors (QSIs) is reviewed, focusing on their ability to control bacterial communication pathways in pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. AuNPs reduce QS by binding to autoinducers, interfering with the QS receptor, and interacting directly with biofilm matrices to result in substantial decreases in biofilm formation and pathogenicity. In addition, functionalized AuNPs exhibit increased specificity and reduced cytotoxicity, making them potential medical tools. Although they have great potential, the safety of AuNPs in human tissue and the environment remains a concern, and current studies focus on reducing particle size, improving surface modifications, and enhancing biodegradability. In addition, the review shows how AuNPs can be combined with conventional antibiotics to achieve better outcomes in multidrug-resistant (MDR) infections. However, current challenges in achieving clinical outcomes persist during production scaling and regulatory approval. Still, AuNPs offer a novel approach to treating chronic, resistant infections, with promising therapeutic opportunities for future antimicrobial therapies.
Indexed as
Identifiers
41999422What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.